Status:

COMPLETED

Systems Pharmacology Approach to Uncontrolled Pediatric Asthma

Lead Sponsor:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborating Sponsors:

University of Maribor, Maribor, Slovenia.

University Children's Hospital, University of Regensburg, Regensburg, Germany

Conditions:

Pediatric Asthma

Uncontrolled Asthma

Eligibility:

All Genders

6-18 years

Brief Summary

Background: Asthma is a heterogeneous respiratory disease and the most common chronic disease in children. A small subset of children has continuous poor asthma control despite appropriate adherence ...

Eligibility Criteria

Inclusion

  • General:
  • Between 6-17 years of age
  • Doctor diagnosis of asthma
  • In addition to the general criteria, a case with uncontrolled asthma (case group A) should meet:
  • Asthma treatment Global INitiative of Asthma (GINA) step 3 or higher
  • ≥ 1of the following criteria (based on the guideline 'Childhood Asthma' of the section paediatric pulmonology of the Dutch Society of Paediatricians, 2007):
  • Frequent exacerbations requiring OCS use (≥1 in the past year) and/or
  • Severe exacerbations requiring hospitalization or ER visits in the past year and/or
  • ACQ/ACT scores indicating uncontrolled asthma
  • In addition to the general criteria, a case with an acute exacerbation (case group B) should meet:
  • Asthma treatment Global INitiative of Asthma (GINA) step 2 or higher
  • Current severe asthma exacerbation requiring hospitalization
  • In addition to the general inclusion criteria, a control (controlled asthma) should meet the following criteria:
  • Asthma treatment Global INitiative of Asthma (GINA) step 3 or higher
  • Lack of severe exacerbations requiring OCS use or hospitalizations or ER visits in the past year
  • ACQ/ACT scores indicating well controlled asthma or few reported asthma symptoms during asthma checks in the past year.

Exclusion

  • Recent use of a course of antibiotics (\< 1 month). This will affect the microbiome analyses.
  • A patient can be re-screened 1 month after the use of the antibiotic treatment has finished.

Key Trial Info

Start Date :

January 12 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 31 2020

Estimated Enrollment :

145 Patients enrolled

Trial Details

Trial ID

NCT04865575

Start Date

January 12 2018

End Date

October 31 2020

Last Update

April 29 2021

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

University Regensburg

Regensburg, Germany

2

Utrecht University

Utrecht, Netherlands

3

University of Maribor

Maribor, Slovenia

4

University of the Basque Country

San Sebastián, Spain